<DOC>
	<DOCNO>NCT01228838</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability NGX-1998 apply 5 minute treatment postherpetic neuralgia ( PHN ) .</brief_summary>
	<brief_title>Study NGX-1998 Treatment Postherpetic Neuralgia</brief_title>
	<detailed_description>This study 12-week multicenter randomize , double-blind , control evaluation efficacy , safety tolerability NGX-1998 treatment postherpetic neuralgia ( PHN ) . Eligible subject pain PHN , average numeric pain rating scale ( NPRS ) score screen 4 9 ( inclusive ) . Painful area 1500 cm2 treat single Test Article application . Subjects randomly assign receive NGX-1998 ( 10 % 20 % w/w ) placebo accord unequal allocation scheme 2:2:1 . Subjects also stratify gender .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Between 18 90 year age , inclusive . Diagnosis PHN least six ( 6 ) month pain since shingle vesicle crust . Average NPRS score PHNassociated pain Days 14 4 4 9 , inclusive . Intact , unbroken skin painful area ( ) treat . If take chronic pain medication , stable ( PRN ) regimen least 21 day prior Test Article Application Visit willing maintain medication stable dose ( ) schedule throughout study . Female subject childbearing potential must negative serum beta human chorionic gonadotropin ( hCG ) pregnancy test , perform within 7 day Test Article Application Visit . All subject must willing use effective method birth control and/or refrain participate conception process study . If breastfeeding , subject agree breastfeed child treatment treatment day . Be willing able comply protocol requirement duration study participation . Subjects must sign informed consent form study approve Investigator 's Institutional Review Board/Independent Ethics Committee ( IRB/IEC ) . Concomitant opioid medication , unless orally transdermally administer exceed total daily dose morphine 60 mg/day , equivalent . Parenteral opioid use exclude . Unavailability effective medication treatment related discomfort subject , unwillingness use opioid analgesic study treatment , high tolerance opioids preclude ability relieve treatmentassociated discomfort . Active substance abuse history chronic substance abuse within past year , prior chronic substance abuse judge likely recur study period . Recent use ( within 21 day precede Test Article Application Visit [ Day 0 ] ) topically apply pain medication painful area . Receipt Qutenza® within 12 month Test Article Application Visit ( Day 0 ) . Subjects receive Qutenza® 12 month Test Article Application Visit ( Day 0 ) , respond also exclude . Participation another drug research study within 30 day precede Test Article Application Visit ( Day 0 ) . Current use Class I antiarrhythmic drug III antiarrhythmic drug . Diabetes mellitus , unless wellcontrolled evidenced HBA1c level less equal nine percent ( 9 % ) . A recent history cardiovascular cerebrovascular event unstable hypertension , unless adequately control medication . Significant pain etiology PHN , example , compressionrelated neuropathy , fibromyalgia arthritis . Painful PHN area locate face , hairline scalp , and/or proximity mucous membrane . Any implanted medical device treatment neuropathic pain . History hypersensitivity capsaicin , local anesthetic component CTLs , Cleansing Gel lidocaine ( 2.5 % ) / prilocaine ( 2.5 % ) topical anesthetic cream . Patients glucose6 phosphate dehydrogenase deficiency . Significant ongoing untreated abnormality condition , include active malignancy define treatment require last five ( 5 ) year , opinion Investigator would interfere ability complete study evaluation AEs . Patients congenital idiopathic methemoglobinemia . Recent history significant medicalsurgical intervention judgment Investigator ; example include limited major surgery percutaneous angioplasty/coronary artery stent placement within past 3 month , receipt immunosuppressive therapy within 3 month , prior Test Article Application Visit [ Day 0 ] . Evidence cognitive impairment include dementia may interfere subject 's ability complete daily pain diary require subject 's recall average PHN pain level past 24 hour .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>postherpetic neuralgia</keyword>
	<keyword>PHN</keyword>
	<keyword>capsaicin</keyword>
	<keyword>herpes zoster</keyword>
	<keyword>shingle</keyword>
	<keyword>analgesic</keyword>
	<keyword>neuropathy</keyword>
</DOC>